EC Number   |
Application |
Reference |
|---|
   3.4.24.B7 | diagnostics |
MMP-26 is a putative early biomarker for human carcinomas |
707115 |
| 3.4.24.B7 | medicine |
all umbilical cord tissues, both control and preeclamptic, express MMP-26 and issue inhibitor of matrix metalloproteinase TIMP-4 in macromolecular complexes. Preeclampsia induces a significant increase in the content and actual activity of MMP-26 in umbilical cord vein and Wharton's jelly. The content of TIMP-4 in preeclamptic umbilical cord vein and Wharton's jelly is reduced. The content of MMP-26 mRNA is lower in umbilical cord arteries and veins, whereas higher in Wharton's jelly in preeclampsia |
753498 |
| 3.4.24.B7 | medicine |
expression of matrilysin-2 is significantly correlated with nuclear beta-catenin expression and MMP-9 expression. Patients with matrilysin-2-positive cancer have significantly shorter overall and disease-free survival periods than those with matrilysin-2 negative cancer. Matrilysin-2 expression retains its significant predictive value for overall and disease-free survival in multivariate analysis. Patients with concomitant expression of matrilysin-2 and MMP-9 have the worst prognosis |
668171 |
| 3.4.24.B7 | medicine |
in astrocytic glioma, MMP-26 expression is significantly associated with the World Health Organization grade. MMP-26 expression is an independent factor for evaluating the prognosis of astrocytic glioma patients |
754946 |
| 3.4.24.B7 | medicine |
matrix metalloproteinase MMP26 level is significantly higher in the resected chondrosarcoma than in the adjacent healthy chondral tissue from patients. Overexpression of MMP26 in SW-1353 cells increases cell invasiveness, while inhibition of MMP26 decreases cell invasiveness. Inhibition of Wnt signaling significantly decreases the effect of MMP26 on cancer cell invasion. A strong correlation is detected between MMP26 levels and the ratio of phosphorylated/total beta-catenin in chondrosarcoma from the patients |
735328 |
| 3.4.24.B7 | medicine |
matrix metalloproteinase-26 is a marker of melanomas and estrogen-dependent carcinomas |
668149 |
| 3.4.24.B7 | medicine |
MMP-26 expression levels in androgen-repressed human prostate cancer cells, transfected with sense or anti-sense MMP-26 cDNA, and in benign, neoplastic, and invasive prostate cancer tissues are directly correlated with those of the pro-apoptotic marker Bax. The MMP-26 protein levels are upregulated in high grade prostate intraepithelial neoplasia and decrease during the course of disease progression |
754226 |
| 3.4.24.B7 | medicine |
MMP-26 is a valuable cancer marker, that contributers favorably to the survival of the estrogen receptor alpha/beta-positive cohort of breast cancer patients |
668157 |
| 3.4.24.B7 | medicine |
MMP-26 may play an integral role during the conversion of HGPIN to invasive cancer and may also serve as marker for early prostate cancer diagnosis |
686006 |
| 3.4.24.B7 | medicine |
slight, but significant, downregulation of MMP-26 in more degenerated intervertebral discs (Thompson grades III, IV and V) compared to healthier discs, while both TGF-beta and latent transforming growth factor-beta binding protein 2 are significantly and strongly upregulated |
719420 |
